Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
mRNA-1195 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| mRNA-1195 Dose Level 1 (Low Dose) | EXPERIMENTAL | Participants will receive 3 intramuscular (IM) injections at dose level 1 (low dose) on a 0-, 2-, and 6-month schedule. |
| mRNA-1195 Dose Level 2 (High Dose) | EXPERIMENTAL | Participants will receive 3 IM injections at dose level 2 (high dose) on a 0-, 2-, and 6-month schedule. |
| Placebo | PLACEBO_COMPARATOR | Participants will receive 3 placebo IM injections on a 0-, 2-, and 6-month schedule. |
| Name | Type | Description |
|---|---|---|
| mRNA-1195 | BIOLOGICAL | IM injection |
| Placebo | BIOLOGICAL | IM injection |
Inclusion Criteria: * Medically stable as determined by Investigator's medical evaluation, which will include assessment of medical history, physical examination, laboratory testing, and review of any previously conducted cardiac monitoring. * Participants who are Epstein-Barr virus (EBV)-seroposit...
Top 17 of 21 competitors
mRNA-1195 is an investigational vaccine developed by Moderna, Inc. for multiple sclerosis. It is designed to target Epstein-Barr virus (EBV) and is currently in Phase 2 clinical development. It has not been approved by any regulatory agency and remains an experimental therapy being studied for relapse prevention in people with multiple sclerosis.
mRNA-1195 is being studied for relapse prevention in adults with multiple sclerosis. The Phase 2 trial enrolls participants aged 18 to 55 years and compares the vaccine against placebo. Because it is investigational, mRNA-1195 is not yet available as a treatment outside of clinical research.
mRNA-1195 targets Epstein-Barr virus, or EBV, a virus in the herpesvirus family. The vaccine is designed to generate an immune response against EBV. The Phase 2 study is testing whether targeting EBV with mRNA-1195 can help prevent relapses in people with multiple sclerosis.
Moderna, Inc. is developing mRNA-1195. Moderna trades on the Nasdaq under the ticker symbol MRNA. The company is running the Phase 2 multiple sclerosis program, which is currently recruiting participants in the United States, Australia, and the United Kingdom.
mRNA-1195 is in Phase 2 clinical development. It is an investigational vaccine and has not been approved by the FDA or any other regulatory authority. The Phase 2 trial is actively recruiting, and no trials of mRNA-1195 have been completed to date.
mRNA-1195 is being studied in one clinical trial, NCT06735248, titled a study to investigate multiple sclerosis relapse prevention with mRNA-1195 compared with placebo in participants aged 18 to 55 years. The Phase 2 trial is randomized, double-blind, and placebo-controlled, with an planned enrollment of 180 participants across the United States, Australia, and the United Kingdom.